metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-32 EVALUATION OF HEPATIC FIBROSIS THROUGH NON-INVASIVE METHODS IN PATIENTS WIT...
Journal Information
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Share
Share
Download PDF
More article options
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Open Access
P-32 EVALUATION OF HEPATIC FIBROSIS THROUGH NON-INVASIVE METHODS IN PATIENTS WITH CHRONIC VIRAL HEPATITIS B AND C
Visits
387
Felipe José de Oliveira Fraga1, Leila Maria Soares Tojal de Barros Lima2
1 Medical Clinic Residence, Professor Alberto Antunes University Hospital, Federal University of Alagoas, Maceió, Brail
2 Department of Gastroenterology, Professor Alberto Antunes University Hospital, Federal University of Alagoas, Maceió Brasil
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 24. Issue S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

More info
Introduction

Biopsy has been considered the method of choice for staging fibrosis in liver disease. However, as it is an invasive method subject to sampling errors and morbidity, new non-invasive methods have been proposed for the assessment of liver fibrosis.

Aims

To evaluate and compare serum fibrosis biomarkers (APRI and FIB4) with transient liver elastography (THE), gold standard in this study in patients with chronic viral hepatitis B and C.

Methods

Cross-sectional study of patients with chronic hepatitis B or C virus undergoing THE. The patients were evaluated using serum liver fibrosis markers APRI and FIB4. The degree of fibrosis ≥ 2 of the Metavir classification was defined as significant fibrosis. The diagnostic performance of both methods was calculated and compared using the ROC curve (AUROC).

Results

The study included 73 patients, 50 with HBV and 23 with HCV; 50.7% were female, mean age 48.6 ± 13.3 years. Significant fibrosis was observed in 31 patients. The accuracy of serum markers in the diagnosis of liver fibrosis was determined by AUROC, APRI 0.79 and FIB4 0.76 (P = .0.42); PPV and NPV APRI 91.7% and 76.9% respectively; FIB4, PPV = 87.5% and NPV = 77.8%.

Conclusion

The study demonstrated that there was no difference in diagnostic performance between the APRI and FIB4 methods, which were considered tests with good accuracy in the diagnosis of significant fibrosis in patients with chronic viral hepatitis.

Full text is only aviable in PDF
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos